Precision medicine is rapidly gaining prominence as a mainstream treatment approach in oncology. Coupled with the rise of precision medicine, oncology has also seen biomarker tests not just entering the mainstream but also shifting the way decisions are made.
Join us as we explore current trends and insights with the evolving landscape of precision medicine and biomarker testing and its impact on oncology markets across different tumor types and geographies.
3 key takeaways:
Vladimir Bonevski
Associate Director, Global Oncology Product & Strategy, IQVIA
Kriti Jindal, M.S. (Pharm.)
Client Service Manager, Global Oncology, IQVIA
Lien Lybaert
Chief Development Officer, myNEO Therapeutics
Unravel the complexities of cancer treatment with patient-level data-driven solutions.
.svg){kind=icon}
